An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters
暂无分享,去创建一个
Y. Liu | K. To | Honglin Chen | K. Yuen | Wenjun Song | Pui Wang | B. Mok | Shaofeng Deng | A. J. Zhang | Teng Long | R. Zhou | Haoran Xu | J. F. Chan | Pin Chen | Zhiwei Chen | Rachel Chun Yee Tam | Anja Kukic
[1] A. Iwasaki,et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses , 2022, Science.
[2] L. Wain,et al. Nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. , 2022, medRxiv.
[3] E. Waltz. How nasal-spray vaccines could change the pandemic , 2022, Nature.
[4] M. Churchill,et al. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern , 2022, eBioMedicine.
[5] K. To,et al. Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters , 2022, Science.
[6] Fei Shao,et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.
[7] P. Earl,et al. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection , 2022, Proceedings of the National Academy of Sciences of the United States of America.
[8] Graham W. Taylor,et al. Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England , 2022, Science.
[9] Luke Taylor. Covid-19: True global death toll from pandemic is almost 15 million, says WHO , 2022, BMJ.
[10] P. Thomas,et al. Mucosal immune responses to infection and vaccination in the respiratory tract , 2022, Immunity.
[11] Huachen Zhu,et al. A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2 , 2022, Science Bulletin.
[12] Ryan T Novak,et al. COVID-19 Mortality and Vaccine Coverage — Hong Kong Special Administrative Region, China, January 6, 2022–March 21, 2022 , 2022, China CDC weekly.
[13] J. Dushoff,et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa , 2022, Science.
[14] D. Altmann,et al. COVID-19 vaccination: The road ahead , 2022, Science.
[15] Cheng-Wei Cheng,et al. Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models , 2022, Science Translational Medicine.
[16] B. Walker,et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals , 2022, Cell.
[17] Liyuan Liu,et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages , 2022, Nature.
[18] Matthew S. Miller,et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2 , 2022, Cell.
[19] A. Sette,et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron , 2022, Nature.
[20] S. Mallal,et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron , 2022, Cell.
[21] K. To,et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron , 2021, Nature.
[22] T. de Oliveira,et al. Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity , 2021, Science Translational Medicine.
[23] Zhiwei Chen,et al. Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models , 2022, EBioMedicine.
[24] A. Iwasaki,et al. Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA , 2021, Science Immunology.
[25] D. Wesemann,et al. Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant , 2021, Science.
[26] T. Randall,et al. Scent of a vaccine , 2021, Science.
[27] R. Scheuermann,et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals , 2021, Cell Reports Medicine.
[28] K. Subbarao. The success of SARS-CoV-2 vaccines and challenges ahead , 2021, Cell Host & Microbe.
[29] D. Fremont,et al. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters , 2021, Cell Reports.
[30] Bryan D. Bryson,et al. Predicting the mutational drivers of future SARS-CoV-2 variants of concern , 2021, Science Translational Medicine.
[31] Edward C. Holmes,et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology , 2020, Nature Microbiology.
[32] Kwok-Hung Chan,et al. Long SARS-CoV-2 nucleocapsid sequences in blood monocytes collected soon after hospital admission , 2020, bioRxiv.
[33] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[34] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[35] K. Subbarao,et al. How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines , 2019, The Journal of infectious diseases.
[36] C. Ehrhardt,et al. Immunomodulatory Nonstructural Proteins of Influenza A Viruses. , 2018, Trends in microbiology.
[37] Thi H. O. Nguyen,et al. Resident memory CD8+ T cells in the upper respiratory tract prevent pulmonary influenza virus infection , 2017, Science Immunology.
[38] K. Kedzierska,et al. Nasal-associated lymphoid tissues (NALTs) support the recall but not priming of influenza virus-specific cytotoxic T cells , 2017, Proceedings of the National Academy of Sciences.
[39] R. Krug,et al. RNA primers and the role of host nuclear RNA polymerase II in influenza viral RNA transcription. , 1980, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[40] J. Atkinson,et al. Decay-Accelerating Factor: Biochemistry, Molecular Biology, and Function , 1989 .